scholarly journals Baricitinib for Refractory Eosinophilic Fasciitis: Myth or Reality?

2021 ◽  
pp. jrheum.211126
Author(s):  
Gang Wang ◽  
Ning Zhuo ◽  
Jingyang Li
Keyword(s):  
Mycophenolate Mofetil ◽  
Treatment Strategy ◽  
Recent Article ◽  
Considerable Improvement ◽  
Janus Kinase ◽  
Eosinophilic Fasciitis ◽  
Aggressive Treatment

We read the recent article by Sehgal et al with great interest.1 The authors described a 37-year-old patient with eosinophilic fasciitis (EF) who showed no improvement after an initial aggressive treatment strategy (intravenous [IV] methylprednisolone, prednisone, methotrexate, mycophenolate mofetil, and IVIG). Subsequently, the use of the Janus kinase ( JAK) 1/2 inhibitor baricitinib resulted in considerable improvement in the patient's symptoms and skin appearance. However, there are some details that need further clarification.

MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin

2020 ◽  
Vol 13 (9) ◽  
pp. e236431
Author(s):  
Kelli Stager ◽  
Leanna Wise
Keyword(s):  
Mycophenolate Mofetil ◽  
Interstitial Lung Disease ◽  
Early Diagnosis ◽  
Lung Disease ◽  
Intravenous Immunoglobulin ◽  
Poor Prognosis ◽  
Aggressive Treatment ◽  
Cutaneous Manifestations ◽  
Severity Of Disease ◽  
Aggressive Management

Antimelanoma differentiation-associated gene 5 (MDA-5) dermatomyositis is a subtype of dermatomyositis that is associated with rapidly progressive interstitial lung disease (RP-ILD), as well as with a variety of cutaneous manifestations. Patients with MDA-5 dermatomyositis tend to have a poor prognosis that is often attributed to the high rates of concurrent RP-ILD. Given the severity of disease, early diagnosis and aggressive management is pivotal. We present a case of a 40-year-old woman diagnosed with MDA-5 dermatomyositis who presented with weakness, painful cutaneous ulcerations and interstitial lung disease. She was treated with monthly intravenous Ig (IVIg), weight-based prednisone and mycophenolate mofetil (MMF). After approximately 2 years of treatment, her interstitial lung disease remains stable and she has had significant improvement in weakness and cutaneous ulcerations. Our case provides evidence for early and aggressive treatment of MDA-5 dermatomyositis with a combination of weight-based prednisone, MMF and IVIg.

Early Aggressive Treatment Strategy against Myasthenia Gravis

2011 ◽  
Vol 65 (1) ◽  
pp. 16-22 ◽  
Author(s):  
Yuriko Nagane ◽  
Shigeaki Suzuki ◽  
Norihiro Suzuki ◽  
Kimiaki Utsugisawa
Keyword(s):  
Myasthenia Gravis ◽  
Treatment Strategy ◽  
Aggressive Treatment

Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review

2021 ◽  
pp. 1-4
Author(s):  
Ilse Andrea Moreno-Arquieta ◽  
Jesus Alberto Cardenas-de la Garza ◽  
Jorge Antonio Esquivel-Valerio ◽  
Janett Riega-Torres ◽  
Adrian Cuellar-Barboza ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Literature Review ◽  
Mycophenolic Acid ◽  
Eosinophilic Fasciitis

scholarly journals Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib

2018 ◽  
Vol 4 (5) ◽  
pp. 443-445 ◽  
Author(s):  
Sa Rang Kim ◽  
Alexandra Charos ◽  
William Damsky ◽  
Peter Heald ◽  
Michael Girardi ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Eosinophilic Fasciitis ◽  
Janus Kinase Inhibitor

scholarly journals Treatment strategies for elderly-onset rheumatoid arthritis in the new era

2021 ◽  
Author(s):  
Takahiko Sugihara
Keyword(s):  
Rheumatoid Arthritis ◽  
Treatment Strategy ◽  
Older Patients ◽  
Joint Destruction ◽  
Treatment Strategies ◽  
Janus Kinase ◽  
Younger Patients ◽  
Age Related ◽  
Elderly Onset ◽  
Elderly Onset Rheumatoid Arthritis

ABSTRACT Elderly-onset rheumatoid arthritis (EORA) is characterized by acute onset and clinical features of high disease activity. Anti-cyclic citrullinated peptide antibody (ACPA) positivity or the presence of bone erosions predicts a radiological joint destruction of EORA, but ACPA-negative EORA with a polymyalgia rheumatica (PMR) phenotype may also present. Biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors were beneficial both in older and in younger patients in terms of risk–benefit balance. Implementation of a treat-to-target strategy could improve EORA outcomes, but older patients have more age-related comorbidities and interstitial lung disease than younger patients. Baseline comorbidities, more frequent methotrexate dose-dependent adverse events, serious infections, cardiovascular disease events, and malignancy all influence the choice of treatment and the treatment goals for older patients. Based on articles reviewed here, it is suggested that current treatment strategies for younger patients are also useful for ACPA-positive EORA and for ACPA-negative EORA with bone erosion. Differential diagnosis of ACPA-negative EORA without erosive arthritis and PMR with peripheral manifestations is challenging, and the treatment strategy of patients presenting with this overlap phenotype remained unclear. An appropriate treatment strategy for all patients with EORA still needs to be developed.

scholarly journals Mycophenolate Mofetil for Eosinophilic Fasciitis

2020 ◽  
Vol 156 (5) ◽  
pp. 595
Author(s):  
Elizabeth Tkachenko ◽  
Alexa B. Steuer ◽  
Kelly Lo ◽  
Avery LaChance ◽  
Joseph F. Merola ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Eosinophilic Fasciitis
Sign in / Sign up

Export Citation Format

Share Document